Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 11/20 | 0.84 |
| ▸ | AKT1 | P31749 | 6/20 | 0.84 |
| ▸ | AKT2 | P31751 | 6/20 | 0.84 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.84 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.70 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.70 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.70 |
| ▸ | SRC | P12931 | 1/20 | 0.70 |
| ▸ | DDX6 | P26196 | 1/20 | 0.70 |
| ▸ | PDE4A | P27815 | 1/20 | 0.70 |
| ▸ | CSK | P41240 | 1/20 | 0.70 |
| ▸ | MTOR | P42345 | 1/20 | 0.70 |
| ▸ | PLK1 | P53350 | 1/20 | 0.70 |
| ▸ | PRKDC | P78527 | 1/20 | 0.70 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.70 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.70 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.70 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.70 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27121195 | 0.92 | PIK3CA (0.79) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL4348197 | 0.91 | PIK3CB (0.84) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL909768 | 0.91 | PIK3CB (0.84) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL4348187 | 0.91 | PIK3CB (0.84) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL27116153 | 0.91 | PIK3CA (1.00) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25952290 | 0.91 | PIK3CA (1.00) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25359198 | 0.91 | PIK3CA (1.00) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL30336052 | 0.91 | PIK3CA (0.69) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25532391 | 0.91 | PIK3CA (0.69) | PIK3CAAKT1AKT2AKT3PIK3CB | |
| SCHEMBL25532385 | 0.91 | PIK3CA (0.69) | PIK3CAAKT1AKT2AKT3PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4577544-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | claimed |
| WO-2024044769-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | claimed |
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4577544-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2025-07-02 | — | — | EP | disclosed |
| US-20250084048-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-03-13 | — | — | US | disclosed |
| EP-4412606-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024044769-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2024044769-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | Mirati Therapeutics, Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023060262-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078120-A1 | SUBSTITUTED PYRIDOPYRIMIDINONES | CBR1, CBR3, CNR1 | PIK3CA 2749/4885AKT1 2105/4885AKT2 2550/4885 |
| US-20250084048-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | PIK3CA 1/4885AKT1 18/4885AKT2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.